Danaher Corporation Q4 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Strong Earnings Report: Danaher Corporation reported a non-GAAP EPS of $2.23 for Q4, surpassing market expectations by $0.04, highlighting the company's robust performance in biotechnology and cash generation capabilities.
- Revenue Growth: The company's Q4 revenue reached $6.84 billion, exceeding expectations by $30 million, reflecting sustained demand and competitiveness in the healthcare market.
- Valuation Assessment: Analysts estimate Danaher's fair value at $250, based on its solid financial performance and market position, indicating future growth potential.
- Industry Conference Presentation: Danaher showcased its business strategy at the 44th Annual J.P. Morgan Healthcare Conference, further solidifying its leadership in the biotechnology sector and attracting investor interest.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 236.710
Low
235.00
Averages
261.57
High
310.00
Current: 236.710
Low
235.00
Averages
261.57
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
